Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q1 2019 · 10-Q
Revenue$7.02M$7.02M+72.5% vs Q1 2018 Net Income-$12.02M-$12.02MN/M vs Q1 2018 EPS Diluted-$7.64-$7.64N/M vs Q1 2018 Operating Income-$11,440,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,997,000N/M Margins · derivedOperating margin-162.9%+168.7 pt vs Q1 2018
Net margin-171.1%+169.2 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end